8 results on '"Gelovani, Juri"'
Search Results
2. Development of a Bioluminescent Nitroreductase Probe for Preclinical Imaging
- Author
-
Vorobyeva, Anzhelika G., primary, Stanton, Michael, additional, Godinat, Aurélien, additional, Lund, Kjetil B., additional, Karateev, Grigory G., additional, Francis, Kevin P., additional, Allen, Elizabeth, additional, Gelovani, Juri G., additional, McCormack, Emmet, additional, Tangney, Mark, additional, and Dubikovskaya, Elena A., additional
- Published
- 2015
- Full Text
- View/download PDF
3. Imaging Long-Term Fate of Intramyocardially Implanted Mesenchymal Stem Cells in a Porcine Myocardial Infarction Model
- Author
-
Perin, Emerson C., primary, Tian, Mei, additional, Marini, Frank C., additional, Silva, Guilherme V., additional, Zheng, Yi, additional, Baimbridge, Fred, additional, Quan, Xin, additional, Fernandes, Marlos R., additional, Gahremanpour, Amir, additional, Young, Daniel, additional, Paolillo, Vincenzo, additional, Mukhopadhyay, Uday, additional, Borne, Agatha T., additional, Uthamanthil, Rajesh, additional, Brammer, David, additional, Jackson, James, additional, Decker, William K., additional, Najjar, Amer M., additional, Thomas, Michael W., additional, Volgin, Andrei, additional, Rabinovich, Brian, additional, Soghomonyan, Suren, additional, Jeong, Hwan-Jeong, additional, Rios, Jesse M., additional, Steiner, David, additional, Robinson, Simon, additional, Mawlawi, Osama, additional, Pan, Tinsu, additional, Stafford, Jason, additional, Kundra, Vikas, additional, Li, Chun, additional, Alauddin, Mian M., additional, Willerson, James T., additional, Shpall, Elizabeth, additional, and Gelovani, Juri G., additional
- Published
- 2011
- Full Text
- View/download PDF
4. Detection of Pancreatic Carcinomas by Imaging Lactose-Binding Protein Expression in Peritumoral Pancreas Using [18F]Fluoroethyl-Deoxylactose PET/CT
- Author
-
Flores, Leo Garcia, primary, Bertolini, Susanna, additional, Yeh, Hsin Hsin, additional, Young, Daniel, additional, Mukhopadhyay, Uday, additional, Pal, Ashutosh, additional, Ying, Yunming, additional, Volgin, Andrei, additional, Shavrin, Aleksandr, additional, Soghomonyan, Suren, additional, Tong, William, additional, Bornmann, William, additional, Alauddin, Mian M., additional, Logsdon, Craig, additional, and Gelovani, Juri G., additional
- Published
- 2009
- Full Text
- View/download PDF
5. PET Imaging of Lung Inflammation with [18F]FEDAC, a Radioligand for Translocator Protein (18 kDa).
- Author
-
Hatori, Akiko, Joji Yui, Yamasaki, Tomoteru, Lin Xie, Kumata, Katsushi, Fujinaga, Masayuki, Yoshida, Yuichiro, Ogawa, Masanao, Nengaki, Nobuki, Kawamura, Kazunori, Fukumura, Toshimitsu, Ming-Rong Zhang, and Gelovani, Juri G.
- Subjects
POSITRON emission tomography ,PNEUMONIA ,GENE expression ,MEDICAL imaging systems ,LUNG diseases ,RESEARCH - Abstract
Purpose: The translocator protein (18 kDa) (TSPO) is highly expressed on the bronchial and bronchiole epithelium, submucosal glands in intrapulmonary bronchi, pneumocytes and alveolar macrophages in human lung. This study aimed to perform positron emission tomography (PET) imaging of lung inflammation with [
18 F]FEDAC, a specific TSPO radioligand, and to determine cellular sources enriching TSPO expression in the lung. Methods: An acute lung injury model was prepared by intratracheal administration of lipopolysaccharide (LPS) to rat. Uptake of radioactivity in the rat lungs was measured with small-animal PET after injection of [18 F]FEDAC. Presence of TSPO was examined in the lung tissue using Western blot and immunohistochemical assays. Results: The uptake of [18 F]FEDAC increased in the lung with the progress of inflammation by treatment with LPS. Pretreatment with a TSPO-selective ligand PK11195 showed a significant decrease in the lung uptake of [18 F]FEDAC due to competitive binding to TSPO. TSPO expression was elevated in the inflamed lung section and its level responded to the [18 F]FEDAC uptake and severity of inflammation. Increase of TSPO expression was mainly found in the neutrophils and macrophages of inflamed lungs. Conclusion: From this study we conclude that PET with [18 F]FEDAC may be a useful tool for imaging TSPO expression and evaluating progress of lung inflammation. Study on human lung using [18 F]FEDAC-PET is promising. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
6. Imaging Characteristics, Tissue Distribution, and Spread of a Novel Oncolytic Vaccinia Virus Carrying the Human Sodium Iodide Symporter.
- Author
-
Haddad, Dana, Chun-Hao Chen, Carlin, Sean, Silberhumer, Gerd, Chen, Nanhai G., Qian Zhang, Longo, Valerie, Carpenter, Susanne G., Mittra, Arjun, Carson, Joshua, Au, Joyce, Gonen, Mithat, Zanzonico, Pat B., Szalay, Aladar A., Fong, Yuman, and Gelovani, Juri G.
- Subjects
CANCER treatment ,PANCREATIC cancer ,POSITRON emission tomography ,VIRAL replication ,HISTOLOGY ,THERAPEUTICS - Abstract
Introduction: Oncolytic viruses show promise for treating cancer. However, to assess therapy and potential toxicity, a noninvasive imaging modality is needed. This study aims to determine the in vivo biodistribution, and imaging and timing characteristics of a vaccinia virus, GLV-1h153, encoding the human sodium iodide symporter (hNIS. Methods:GLV-1h1 53 was modified from GLV-1h68 to encode the hNIS gene. Timing of cellular uptake of radioiodide
131 I in human pancreatic carcinoma cells PANC-1 was assessed using radiouptake assays. Viral biodistribution was determined in nude mice bearing PANC-1 xenografts, and infection in tumors confirmed histologically and optically via Green Fluorescent Protein (GFP) and bioluminescence. Timing characteristics of enhanced radiouptake in xenografts were assessed via124 I-positron emission tomography (PET). Detection of systemic administration of virus was investigated with both124 I-PET and 99m-technecium gamma- scintigraphy. Results: GLV-1 h1 53 successfully facilitated time-dependent intracellular uptake of 131I in PANC-1 cells with a maximum uptake at 24 hours postinfection (P,0.05). In vivo, biodistribution profiles revealed persistence of virus in tumors 5 weeks postinjection at 109 plaque-forming unit (PFU)/gm tissue, with the virus mainly cleared from all other major organs. Tumor infection by GLV-1 h1 53 was confirmed via optical imaging and histology. GLV-1 h1 53 facilitated imaging virus replication in tumors via PET even at 8 hours post radiotracer injection, with a mean %ID/gm of 3.82±0.46 (P<0.05) 2 days after intratumoral administration of virus, confirmed via tissue radiouptake assays. One week post systemic administration, GLV-1h153-infected tumors were detected via124 I-PET and 99m-technecium-scintigraphy. Conclusion: GLV-1 h1 53 is a promising oncolytic agent against pancreatic cancer with a promising biosafety profile. GLV-1 h1 53 facilitated time-dependent hNIS- specific radiouptake in pancreatic cancer cells, facilitating detection by PET with both intratumoral and systemic administration. Therefore, GLV-1 h1 53 is a promising candidate for the noninvasive imaging of virotherapy and warrants further study into longterm monitoring of virotherapy and potential radiocombination therapies with this treatment and imaging modality. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
7. Detection of Pancreatic Carcinomas by Imaging Lactose- Binding Protein Expression in Peritumoral Pancreas Using [18F]Fluoroethyl-Deoxylactose PET/CT.
- Author
-
Flores, Leo Garcia, Bertolini, Susanna, Yeh, Hsin Hsin, Young, Daniel, Mukhopadhyay, Uday, Pal, Ashutosh, Ying, Yunming, Volgin, Andrei, Shavrin, Aleksandr, Soghomonyan, Suren, Tong, William, Bornmann, William, Alauddin, Mian M., Logsdon, Craig, and Gelovani, Juri G.
- Abstract
Background: Early diagnosis of pancreatic carcinoma with highly sensitive diagnostic imaging methods could save lives of many thousands of patients, because early detection increases resectability and survival rates. Current non-invasive diagnostic imaging techniques have inadequate resolution and sensitivity for detection of small size (,2–3 mm) early pancreatic carcinoma lesions. Therefore, we have assessed the efficacy of positron emission tomography and computer tomography (PET/CT) imaging with γ-O-D-galactopyranosyl-(1,49)-29-deoxy-29-[
18 F]fluoroethyl-D-glucopyranose ([18F]FEDL) for detection of less than 3 mm orthotopic xenografts of L3.6pl pancreatic carcinomas in mice. [18 F]FEDL is a novel radioligand of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein (HIP/PAP), which is overexpressed in peritumoral pancreatic acinar cells. Methodology/Principal Findings: Dynamic PET/CT imaging demonstrated rapid accumulation of [18 F]FEDL in peritumoral pancreatic tissue (4.0462.06%ID/g), bi-exponential blood clearance with half-lives of 1.6560.50 min and 14.1463.60 min, and rapid elimination from other organs and tissues, predominantly by renal clearance. Using model-independent graphical analysis of dynamic PET data, the average distribution volume ratio (DVR) for [18 F]FEDL in peritumoral pancreatic tissue was estimated as 3.5760.60 and 0.9460.72 in sham-operated control pancreas. Comparative analysis of quantitative autoradiographic images and densitometry of immunohistochemically stained and co-registered adjacent tissue sections demonstrated a strong linear correlation between the magnitude of [18 F]FEDL binding and HIP/PAP expression in corresponding regions (r = 0.88). The in situ analysis demonstrated that at least a 2–4 fold apparent lesion size amplification was achieved for submillimeter tumors and to nearly half a murine pancreas for tumors larger than 3 mm. Conclusion/Significance: We have demonstrated the feasibility of detection of early pancreatic tumors by non-invasive imaging with [18 F]FEDL PET/CT of tumor biomarker HIP/PAP over-expressed in peritumoral pancreatic tissue. Non-invasive non-invasive detection of early pancreatic carcinomas with [18 F]FEDL PET/CT imaging should aid the guidance of biopsies and additional imaging procedures, facilitate the resectability and improve the overall prognosis. [ABSTRACT FROM AUTHOR]- Published
- 2009
- Full Text
- View/download PDF
8. Tumor-Targeting Salmonella typhimurium A1-R in Combination with Trastuzumab Eradicates HER-2-Positive Cervical Cancer Cells in Patient-Derived Mouse Models
- Author
-
Masashi Momiyama, Ming Zhao, Ryusei Matsuyama, Ali Maawy, Yasushi Ichikawa, Ryutaro Mori, Itaru Endo, Robert M. Hoffman, Shinji Miwa, Takashi Murakami, Sumiyuki Mii, Michael Bouvet, Yukihiko Hiroshima, Takashi Chishima, Yong Zhang, Nan Zhang, Fuminari Uehara, Shuya Yano, Mako Yamamoto, Kuniya Tanaka, and Gelovani, Juri G
- Subjects
Salmonella typhimurium ,Salmonella ,Pathology ,Tumor targeting ,Receptor, ErbB-2 ,Nude ,lcsh:Medicine ,Uterine Cervical Neoplasms ,medicine.disease_cause ,Mice ,ErbB-2 ,0302 clinical medicine ,Trastuzumab ,lcsh:Science ,Cancer ,Cervical cancer ,Heterologous ,0303 health sciences ,Multidisciplinary ,biology ,Immunohistochemistry ,3. Good health ,030220 oncology & carcinogenesis ,Female ,Antibody ,Research Article ,Receptor ,medicine.drug ,medicine.medical_specialty ,Stromal cell ,General Science & Technology ,Transplantation, Heterologous ,Mice, Nude ,Vaccine Related ,03 medical and health sciences ,Breast Cancer ,medicine ,Animals ,Humans ,In patient ,030304 developmental biology ,Transplantation ,Animal ,business.industry ,Prevention ,lcsh:R ,medicine.disease ,Brain Disorders ,Disease Models, Animal ,Emerging Infectious Diseases ,Disease Models ,biology.protein ,Cancer research ,lcsh:Q ,Digestive Diseases ,business - Abstract
We have previously developed mouse models of HER-2-positive cervical cancer. Tumors in nude mice had histological structures similar to the original tumor and were stained by anti-HER-2 antibody in the same pattern as the patient's cancer. We have also previously developed tumor-targeting Salmonella typhimurium A1-R and have demonstrated its efficacy against patient-derived tumor mouse models, both alone and in combination. In the current study, we determined the efficacy of S. typhimurium A1-R in combination with trastuzumab on a patient-cancer nude-mouse model of HER-2 positive cervical cancer. Mice were randomized to 5 groups and treated as follows: (1) no treatment; (2) carboplatinum (30 mg/kg, ip, weekly, 5 weeks); (3) trastuzumab (20 mg/kg, ip, weekly, 5 weeks); (4) S. typhimurium A1-R (5 × 107 CFU/body, ip, weekly, 5 weeks); (5) S. typhimurium A1-R (5 × 107 CFU/body, ip, weekly, 5 weeks) + trastuzumab (20 mg/kg, ip, weekly, 5 weeks). All regimens had significant efficacy compared to the untreated mice. The relative tumor volume of S. typhimurium A1-R + trastuzumab-treated mice was smaller compared to trastuzumab alone (p = 0.007) and S. typhimurium A1-R alone (p = 0.039). No significant body weight loss was found compared to the no treatment group except for carboplatinum-treated mice (p = 0.021). Upon histological examination, viable tumor cells were not detected, and replaced by stromal cells in the tumors treated with S. typhimurium A1-R + trastuzumab. The results of the present study suggest that S. typhimurium A1-R and trastuzumab in combination are highly effective against HER-2-expressing cervical cancer.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.